Skip to main content
FENC $11.62 +6.61%
FENC logo
FENC · Fennec Pharmaceuticals Inc.
Track FENC — free
$11.62 +0.72 (+6.61%) At close · Nov 13 Play latest call Q2 2026 earnings call transcript
Market Cap
$410.25M
Shares
35.31M
Volume · Nov 13 461.31K Avg daily vol (3M) 185.19K
All webcasts

Earnings call · FY2026 Q3

Fennec Pharmaceuticals Inc. (FENC) Q3 2026 Earnings Call

Concluded Nov 12, 2026
Nov 12, 2026
Period
FY2026 Q3
Runtime
—
Sources
1 artifact
Revenue $19.61M +57.3% YoY
Diluted EPS $0.12
Net income $4.64M
Open full screen 10-Q

Executive readout · one minute

What the filings say

10-Q report · filed Nov 12, 2026
Fennec's nine-month PEDMARK sales rose $20,832, or 67%, to $51,697, while net income reached $6,814 versus a $4,954 loss. The Cipla settlement bars generic U.S. entry until September 1, 2033, or earlier under certain specified circumstances.

The audio replay and transcript follow the call.

Research coverage

1 live source

Open each available source without leaving this research workspace.

Research materials

Open the source you need; every reader stays inside this workspace.

Quarter detail

How the reported period landed and where the business moved.

Revenue · products & services

Manufactured Product Other$19.43M +55.9% YoY
Service Other$183,000
Full-screen source Call document